Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)Elias Jabbour, Andreas Hochhaus, Giuseppe Saglio et al.|Blood|2013Cited by 391